ABBV - Prometheus Biosciences Starts $125 Million IPO Plan February, 25 2021 04:53 PM AbbVie Inc. Prometheus Biosciences has filed to raise $125 million in a U.S IPO. The firm is developing treatments for inflammatory bowel disease conditions. RXDX is in Phase 1 safety trials for its lead candidate for the treatment of ulcerative colitis and Crohn's disease. For further details see: Prometheus Biosciences Starts $125 Million IPO Plan